Stock Track | MannKind (MNKD) Soars 5.84% Pre-Market on Strong Q3 Results, Beating EPS Estimates by 233%

Stock Track

Nov 05, 2025

MannKind Corporation (NASDAQ: MNKD) saw its stock surge 5.84% in pre-market trading on Wednesday following the release of its impressive third-quarter 2025 financial results. The biopharmaceutical company significantly outperformed analyst expectations, demonstrating robust growth and operational efficiency.

The company reported quarterly earnings of $0.07 per share, surpassing the analyst consensus estimate of $0.02 by a remarkable 233.33%. This represents a 16.67% increase compared to earnings of $0.06 per share in the same period last year. MannKind's quarterly sales reached $82.130 million, beating the analyst consensus estimate of $80.255 million by 2.34% and marking a 17.20% increase from $70.079 million in the previous year.

Other notable financial highlights include a net income of $7.985 million and an operating income of $18.896 million for the quarter. The company's year-to-date revenues for 2025 reached $237.0 million, up 14% from the same period in 2024. MannKind also reported a strong cash position, with cash, cash equivalents, and investments totaling $286.3 million as of September 30, 2025. Additionally, the company announced positive developments in its product pipeline, including FDA acceptance of the Afrezza supplemental Biologics License Application for pediatric use, with a PDUFA date set for May 29, 2026. These factors collectively contributed to the significant pre-market stock price increase, reflecting investor confidence in MannKind's growth trajectory and future prospects.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1122376498"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1122376498\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1122376498?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-05 21:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1122376498","market":"nz","top_or_hot":-1,"title":"Stock Track | MannKind (MNKD) Soars 5.84% Pre-Market on Strong Q3 Results, Beating EPS Estimates by 233%","media":"Stock Track","content":"<p>MannKind Corporation (NASDAQ: MNKD) saw its stock surge 5.84% in pre-market trading on Wednesday following the release of its impressive third-quarter 2025 financial results. The biopharmaceutical company significantly outperformed analyst expectations, demonstrating robust growth and operational efficiency.</p>\n\n<p>The company reported quarterly earnings of $0.07 per share, surpassing the analyst consensus estimate of $0.02 by a remarkable 233.33%. This represents a 16.67% increase compared to earnings of $0.06 per share in the same period last year. MannKind's quarterly sales reached $82.130 million, beating the analyst consensus estimate of $80.255 million by 2.34% and marking a 17.20% increase from $70.079 million in the previous year.</p>\n\n<p>Other notable financial highlights include a net income of $7.985 million and an operating income of $18.896 million for the quarter. The company's year-to-date revenues for 2025 reached $237.0 million, up 14% from the same period in 2024. MannKind also reported a strong cash position, with cash, cash equivalents, and investments totaling $286.3 million as of September 30, 2025. Additionally, the company announced positive developments in its product pipeline, including FDA acceptance of the Afrezza supplemental Biologics License Application for pediatric use, with a PDUFA date set for May 29, 2026. These factors collectively contributed to the significant pre-market stock price increase, reflecting investor confidence in MannKind's growth trajectory and future prospects.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | MannKind (MNKD) Soars 5.84% Pre-Market on Strong Q3 Results, Beating EPS Estimates by 233%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | MannKind (MNKD) Soars 5.84% Pre-Market on Strong Q3 Results, Beating EPS Estimates by 233%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-05 21:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>MannKind Corporation (NASDAQ: MNKD) saw its stock surge 5.84% in pre-market trading on Wednesday following the release of its impressive third-quarter 2025 financial results. The biopharmaceutical company significantly outperformed analyst expectations, demonstrating robust growth and operational efficiency.</p>\n\n<p>The company reported quarterly earnings of $0.07 per share, surpassing the analyst consensus estimate of $0.02 by a remarkable 233.33%. This represents a 16.67% increase compared to earnings of $0.06 per share in the same period last year. MannKind's quarterly sales reached $82.130 million, beating the analyst consensus estimate of $80.255 million by 2.34% and marking a 17.20% increase from $70.079 million in the previous year.</p>\n\n<p>Other notable financial highlights include a net income of $7.985 million and an operating income of $18.896 million for the quarter. The company's year-to-date revenues for 2025 reached $237.0 million, up 14% from the same period in 2024. MannKind also reported a strong cash position, with cash, cash equivalents, and investments totaling $286.3 million as of September 30, 2025. Additionally, the company announced positive developments in its product pipeline, including FDA acceptance of the Afrezza supplemental Biologics License Application for pediatric use, with a PDUFA date set for May 29, 2026. These factors collectively contributed to the significant pre-market stock price increase, reflecting investor confidence in MannKind's growth trajectory and future prospects.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MNKD","symbol_name":"曼恩凯德生物医疗","start_time":0,"source_url":"","article_id":"1122376498","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1122376498","pubTimestamp":1762348114,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"MannKind Corporation (NASDAQ: MNKD) saw its stock surge 5.84% in pre-market trading on Wednesday following the release of its impressive third-quarter 2025 financial results. The biopharmaceutical...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MNKD":"曼恩凯德生物医疗"},"translate_title":"股票追踪|MannKind(MNKD)因强劲的第三季度业绩盘前飙升5.84%，每股收益超出预期233%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MNKD":1},"content_text":"MannKind Corporation (NASDAQ: MNKD) saw its stock surge 5.84% in pre-market trading on Wednesday following the release of its impressive third-quarter 2025 financial results. The biopharmaceutical company significantly outperformed analyst expectations, demonstrating robust growth and operational efficiency.\nThe company reported quarterly earnings of $0.07 per share, surpassing the analyst consensus estimate of $0.02 by a remarkable 233.33%. This represents a 16.67% increase compared to earnings of $0.06 per share in the same period last year. MannKind's quarterly sales reached $82.130 million, beating the analyst consensus estimate of $80.255 million by 2.34% and marking a 17.20% increase from $70.079 million in the previous year.\nOther notable financial highlights include a net income of $7.985 million and an operating income of $18.896 million for the quarter. The company's year-to-date revenues for 2025 reached $237.0 million, up 14% from the same period in 2024. MannKind also reported a strong cash position, with cash, cash equivalents, and investments totaling $286.3 million as of September 30, 2025. Additionally, the company announced positive developments in its product pipeline, including FDA acceptance of the Afrezza supplemental Biologics License Application for pediatric use, with a PDUFA date set for May 29, 2026. These factors collectively contributed to the significant pre-market stock price increase, reflecting investor confidence in MannKind's growth trajectory and future prospects.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}